Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $280.05 -0.43%
Financial Fact:
Amortization of intangibles: 11.83M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Financial Fact:
Amortization of intangibles: 11.83M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
